<DOC>
	<DOCNO>NCT02619760</DOCNO>
	<brief_summary>The purpose study evaluate safety reduce dual antiplatelet therapy ( DAPT ) duration 1 month implantation everolimus-eluting cobalt-chromium stent ( CoCr-EES ) .</brief_summary>
	<brief_title>ShorT OPtimal Duration Dual AntiPlatelet Therapy-2 Study</brief_title>
	<detailed_description>The drug-eluting stent ( DESs ) currently use majority percutaneous coronary intervention ( PCI ) procedure . On hand , problem first-generation DES ( late adverse event , late stent thrombosis ) point . Dual antiplatelet therapy ( DAPT ) become standard regimen DES implantation fear late stent thrombosis , DAPT frequently perform 1 year longer clinical practice . However , serious hemorrhagic complication associate prolonged DAPT duration bring disadvantage patient , extremely important clarify optimal DAPT duration DES procedure . Currently , 1-month DAPT regimen bare metal stent ( BMS ) implantation commonly use clinical practice , produce major problem . Based meta-analysis recent clinical study , also report use Cobalt-Chromium Everolimus-Eluting Stent ( CoCr-EES ) reduce risk early stent thrombosis half compare use BMS . There necessity extend antiplatelet therapy CoCr-EES implantation longer BMS implantation , consider possible use 1-month DAPT duration BMS implantation . We therefore planned multicenter , randomize , open-label , control study , subject undergone CoCr-EES procedure dive 1-month DAPT clopidogrel monotherapy group 12-month DAPT aspirin monotherapy group . Primary endpoint incidence composite event include cardiovascular death , myocardial infarction , stent thrombosis , stroke , bleed define TIMI major minor bleeding . At first , non-inferiorty primary endpoint 1-month DAPT group evaluate 12 month index procedure secondarily , superiority primary endpoint 1-month DAPT group evaluate 5 year index procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
	<criteria>Patients receive percutaneous coronary intervention cobaltchromium everolimuseluting stent Patients capable oral dual antiplatelet therapy consist asprin P2Y12 receptor antagonist Patients require oral anticoagulant Patients medical history intracranial hemorrhage Patients experience serious complication ( myocardial infarction , stroke , major bleed ) hospital stay percutaneous coronary intervention Patients drug elute stent Cobalt chromium everolimus elute stent ( Xience ) implant time enrollment Patients comfirmed tolerability clopidgorel enrollment Patients require continuous administration antiplaelet drug aspirin P2Y12 receptor antagonist time enrollment Patients coronary bioabsorbable vascular scaffold ( BVS ) implant prior time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
</DOC>